Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib plus azacitidine versus placebo plus azacitidine in previously untreated IDH1-mutated acute myeloid leukemia
2016-004907-30Phase 3Active
- Sponsor
- Agios Pharmaceuticals
- Start
- Jun 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Ivosidenib + azacitidine with Placebo + azacitidine (2 arms). Primary endpoint: Overall survival. Started Jun 2017; status: active.
02
Drugs
ivosidenibazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2016-004907-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004907-30.